Biomarkers Industry Data Book Covers Cardiac & Cancer Biomarkers, Non-alcoholic Steatohepatitis Biomarkers, Global Neurological Biomarkers Markets.
The global biomarkers markets combine to account for USD 41.62 billion revenue in 2021, which is expected to reach USD 137.76 billion by 2030, growing at a cumulative rate of 14.2% over the forecast period.
Cardiac Biomarkers Market Report Highlights
The global cardiac biomarkers market size was valued at USD 13.98 billion in 2021 and it is expected to reach USD 47.88 billion by 2030. It is expected to expand at a CAGR of 14.7% from 2022 to 2030.
- By type, the troponin segment held the largest revenue share in 2021 owing to its high usage in cardiovascular diseases diagnosis
- Based on application, the acute coronary syndrome segment is expected to grow at a lucrative rate during the forecast period due to the increasing prevalence of coronary diseases and expanding applications of these biomarkers in the diagnosis and treatment of diseases
- North America dominated the global market in 2021 owing to the presence of a developed healthcare system that facilitates easier adoption of cardiac biomarkers as a tool for diagnosis and prognosis
- Asia Pacific is expected to grow at a significant rate during the forecast period. This can be attributed to the presence of a wide target population and leading companies that are making R&D investments in countries such as China and Japan
Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights
The global non-alcoholic steatohepatitis biomarkers market size was estimated at USD 982.15 million in 2022 and it is expected to reach USD 5.4 billion by 2030, registering a CAGR of 23.6% during the forecast period,
- By type, the serum biomarkers segment held a larger share of the NASH biomarkers market since serum biomarkers are most effective and most widely used diagnosis tool
- By end-use, the pharma & CRO industry segment is expected to show the fastest growth over the forecast period due to the high demand for non-invasive tools for the diagnosis of liver diseases
- North America dominated the global market in 2022, owing to the rising prevalence of infectious diseases, cardiovascular diseases, and cancer
- Key players operating in the market are focusing on collaborations and partnerships focusing on expanding the awareness about early diagnosis and presence of diagnostic tools for determining NAFLD and NASH
Access the Global Biomarkers Industry Data Book, 2022 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competition benchmarking, macro-environmental analyses, and regulatory & technological framework studies
Cancer Biomarkers Market Report Highlights
The global cancer biomarkers market size was valued at USD 19.99 billion in 2021 and it is expected to reach a value of USD 33.7 billion by 2025, at a CAGR of 13.9% CAGR (2022-2030).
- Breast cancer was the largest segment by revenue share in 2016 owing to high prevalence of this type of cancer
- Lung cancer is estimated to be the fastest-growing type due to increasing research activities toward development of novel lung cancer biomarkers
- Genetic biomarkers, being the highest used and easily detectable held the majority share of cancer biomarker market by biomolecule in 2016
- However, epigenetic biomarkers are anticipated to witness lucrative growth due to increasing focus on finding the role of epigenetic modifications in cancer development
- Cancer biomarkers are majorly used for diagnostic purpose owing to their high specificity
- The personalized medicine segment is estimated to witness fastest CAGR of 15.0% over the forecast period
- North America dominated in terms of revenue share in 2016 due to established R&D infrastructure and high acceptance of biomarker-based cancer testing in this region
- Asia Pacific is anticipated to grow at a substantial growth rate till 2025 with CAGR of over 16.7%
- Some of the major companies in the cancer biomarkers market are Abbott Laboratories; F.Hoffmann-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific Inc.; Affymetrix Inc.; Illumina, Inc.; Agilent Technologies; Merck & Co. Inc.; Hologic, Inc.; Sino Biological Inc.; and Becton, Dickinson and Company
Neurological Biomarkers Market Report Highlights
The global neurological biomarkers market size was valued at USD 6.85 billion in 2021 and it is expected to reach USD 16.14 billion by 2028. The market is expected to grow at a CAGR of 12.8% CAGR (2022-2030).
- Increasing collaborations and public-private partnerships for research initiatives may fuel market growth
- For instance, in February 2018, MJFF in collaboration with the NIH and five life-sciences companies provided USD 24 million as a research grant for the development of neurological biomarkers
- In 2020, the proteomic biomarkers segment accounted for the largest market share and is anticipated to maintain its dominance over the forecast period
- The Parkinson’s disease segment led the market in 2020. An increasing number of clinical trials for Parkinson’s disease drugs and the growing prevalence of the disease is expected to drive the segment growth in the years to come
- North America was the largest regional market in 2020 owing to the high disease burden, acceptance of biomarkers for diagnostic, prognostics, & drug development purposes, and increase in research funding
- Asia Pacific is anticipated to witness the fastest CAGR over the forecast period owing to a rising number of clinical trials being conducted in developing countries, such as India and China, increasing disease burden, and growing need for targeted drugs in the central nervous system
Order your copy of the Free Sample of “Biomarkers Industry Data Book - Cardiac & Cancer Biomarkers, Non-alcoholic Steatohepatitis Biomarkers, Global Neurological Biomarkers Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research
Competitive Landscape
Key players operating in the biomarkers industry are –
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Bio-Rad Laboratories
- Epigenomics AG
- Thermo Fisher Scientific, Inc.
- Siemens Healthineers AG
- Johnson & Johnson Services, Inc
- QIAGEN N.V.
Grand View Research’s biomarkers industry data book is a collection of market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.
Go through the table of content of biomarkers Industry Data Book to get a better understanding of the Coverage & Scope of the study
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: Micro Markets
